Dexcom Released 2026 State of Type 2 Diabetes Report
The findings highlight ongoing barriers to continuous glucose monitor adoption for patients globally.
Updated on Sept. 28, 2026 in Diabetes
Live Poll
Do you believe constant digital health monitoring helps you better manage your daily health decisions?
Dexcom has published its 2026 State of Type 2 Report, detailing insights from 800 healthcare professionals and 2,500 patients across eight countries. The report identifies significant gaps in patient knowledge and reimbursement hurdles as primary factors impacting the use of continuous glucose monitoring (CGM) technology.
Why it matters
Understanding these adoption barriers is critical for improving diabetes management outcomes, especially as the pairing of CGM technology with GLP-1 medications gains traction. The data underscores that while most users feel more independent, systemic and educational challenges remain.
The report surveyed 800 healthcare professionals and 2,500 people with Type 2 diabetes across eight countries. Notably, 58% of patients on GLP-1 medications currently pair their treatment with CGM technology.
The players
Dexcom
This corporation is a leading manufacturer of continuous glucose monitoring technology for diabetes management.
Team Novo Nordisk
This is a professional cycling team comprised entirely of athletes living with diabetes.
The details
The report was released alongside a new partnership between Dexcom and Team Novo Nordisk, an all-diabetes professional cycling team. Findings suggest that 89% of surveyed clinicians believe CGM helps assess treatment adherence, though over half of patients report limited knowledge of the devices.
Timeline
The report was released on September 28, 2026.
The EASD conference in Milan runs from September 28, 2026, through October 2, 2026.
The Big Picture
The report's timing highlights its importance within the global clinical framework established by the European Association for the Study of Diabetes (EASD) annual conference. It follows a pattern set by industry leaders using major medical summits to disseminate patient survey data for clinical influence.
Patients may face significant confusion regarding CGM accessibility due to regional reimbursement differences highlighted in the report. Consulting with a healthcare provider about insurance coverage and potential integration with GLP-1 therapy can clarify individual options for improving diabetes management.
The takeaway
Patients should actively advocate for CGM technology with their clinicians to overcome perceived knowledge gaps and reimbursement hurdles. Leveraging these digital tools can lead to greater self-sufficiency in managing blood glucose levels long-term.
Further reading
Learn more about the latest research and management strategies in the Diabetes section.
More information
View the complete findings in the Dexcom State of Type 2 Report.
Live Poll
Do you believe constant digital health monitoring helps you better manage your daily health decisions?
